Literature DB >> 21344239

Prospective study on association between plasma amyloid beta-42 and atherosclerotic risk factors.

Imrich Blasko1, Georg Kemmler, Susanne Jungwirth, Ildiko Wichart, Silvia Weissgram, Kurt Jellinger, Karl Heinz Tragl, Peter Fischer.   

Abstract

An association between plasma Amyloid beta peptides (Aβ) with blood lipids was reported in cross-sectional studies. The present study examined the 5-year prospective association of atherosclerotic risk factors with plasma Aβ42 in 440 elderly persons without both Alzheimer's disease (AD) or mild cognitive impairment (MCI) at baseline. Persons in the highest tertile of total cholesterol (TC) or LDL-C at baseline showed low plasma Aβ42 at 5 years. Regression analysis confirmed TC and LDL-C as negative predictors of Aβ42 (p = 0.001). An increase over 5 years of HDL-C was a negative predictor and the presence of an APOE ε4 allele was a positive predictor for decrease of Aβ42 in converters to MCI. In converters to AD, increase of both TC and of HbA1c were positive predictors of Aβ42 levels at 5 years. Analysis of covariance showed a positive association between Δ-TC, Δ-LDL-C, Δ-HbA1c, and levels of Aβ42 at 5 years (p = 0.006; 0.013 and 0.027 resp.) in converters to AD independently on lipid-lowering treatment. The association of vascular risk factors TC, LDL-C, and HbA1c with higher Aβ42 levels might, after confirmation in other cohorts, influence the development of lifestyle interventions concerning plasma Aβ42 and AD.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21344239     DOI: 10.1007/s00702-011-0599-4

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  40 in total

1.  Diagnostic impact of CSF biomarkers in a local hospital memory clinic.

Authors:  Maartje I Kester; Leo Boelaarts; Femke H Bouwman; Raymond L Vogels; Erwin R Groot; Evert J van Elk; Marinus A Blankenstein; Wiesje M van der Flier; Philip Scheltens
Journal:  Dement Geriatr Cogn Disord       Date:  2010-06-03       Impact factor: 2.959

2.  Conversion from subtypes of mild cognitive impairment to Alzheimer dementia.

Authors:  P Fischer; S Jungwirth; S Zehetmayer; S Weissgram; S Hoenigschnabl; E Gelpi; W Krampla; K H Tragl
Journal:  Neurology       Date:  2007-01-23       Impact factor: 9.910

3.  Glycosylated hemoglobin level and development of mild cognitive impairment or dementia in older women.

Authors:  K Yaffe; T Blackwell; R A Whitmer; K Krueger; E Barrett Connor
Journal:  J Nutr Health Aging       Date:  2006 Jul-Aug       Impact factor: 4.075

4.  Serum lipid levels and cognitive change in late life.

Authors:  Chandra A Reynolds; Margaret Gatz; Jonathan A Prince; Stig Berg; Nancy L Pedersen
Journal:  J Am Geriatr Soc       Date:  2010-03       Impact factor: 5.562

5.  Serum total cholesterol, apolipoprotein E epsilon 4 allele, and Alzheimer's disease.

Authors:  I L Notkola; R Sulkava; J Pekkanen; T Erkinjuntti; C Ehnholm; P Kivinen; J Tuomilehto; A Nissinen
Journal:  Neuroepidemiology       Date:  1998       Impact factor: 3.282

6.  Normal ranges of neuropsychological tests for the diagnosis of Alzheimer's disease.

Authors:  M Berres; A U Monsch; F Bernasconi; B Thalmann; H B Stähelin
Journal:  Stud Health Technol Inform       Date:  2000

7.  Vienna Transdanube Aging "VITA": study design, recruitment strategies and level of participation.

Authors:  P Fischer; S Jungwirth; W Krampla; S Weissgram; W Kirchmeyr; W Schreiber; K Huber; M Rainer; P Bauer; K H Tragl
Journal:  J Neural Transm Suppl       Date:  2002

8.  Hypercholesterolemia accelerates the Alzheimer's amyloid pathology in a transgenic mouse model.

Authors:  L M Refolo; B Malester; J LaFrancois; T Bryant-Thomas; R Wang; G S Tint; K Sambamurti; K Duff; M A Pappolla
Journal:  Neurobiol Dis       Date:  2000-08       Impact factor: 5.996

9.  Atherosclerosis and AD: analysis of data from the US National Alzheimer's Coordinating Center.

Authors:  Lawrence S Honig; Walter Kukull; Richard Mayeux
Journal:  Neurology       Date:  2005-02-08       Impact factor: 9.910

10.  The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part I. Clinical and neuropsychological assessment of Alzheimer's disease.

Authors:  J C Morris; A Heyman; R C Mohs; J P Hughes; G van Belle; G Fillenbaum; E D Mellits; C Clark
Journal:  Neurology       Date:  1989-09       Impact factor: 9.910

View more
  3 in total

1.  The demographic and medical correlates of plasma aβ40 and aβ42.

Authors:  Andrea L Metti; Jane A Cauley; Hilsa N Ayonayon; Tamara B Harris; Caterina Rosano; Jeff D Williamson; Kristine Yaffe
Journal:  Alzheimer Dis Assoc Disord       Date:  2013 Jul-Sep       Impact factor: 2.703

2.  Abca1 deficiency affects Alzheimer's disease-like phenotype in human ApoE4 but not in ApoE3-targeted replacement mice.

Authors:  Nicholas F Fitz; Andrea A Cronican; Muzamil Saleem; Abdul H Fauq; Robert Chapman; Iliya Lefterov; Radosveta Koldamova
Journal:  J Neurosci       Date:  2012-09-19       Impact factor: 6.167

3.  Population Difference in the Associations of KLOTH Promoter Methylation with Mild Cognitive Impairment in Xinjiang Uygur and Han Populations.

Authors:  Mei Luo; Xiaohui Zhou; Huihui Ji; Wenjuan Ma; Guili Liu; Dongjun Dai; Jingyun Li; Lan Chang; Lei Xu; Liting Jiang; Shiwei Duan; Qinwen Wang
Journal:  PLoS One       Date:  2015-07-21       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.